Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Digirad in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.52.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in Digirad. This rating changed within the last month from a Buy consensus rating.
Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through five segments: Diagnostic Services, Diagnostic Imaging, Mobile Healthcare, Building and Construction, and Real Estate and Investments. The company offers imaging and monitoring services to healthcare providers; and contract diagnostic imaging, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to hospitals, integrated delivery networks, and federal institutions on a long-term contract basis, as well as provisional services to institutions that are in transition. It also develops, sells, and maintains solid-state gamma cameras, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; and manages real estate assets and investments. Digirad Corporation was founded in 1985 and is headquartered in Suwanee, Georgia.